Idorsia Ltd. IDIA

BioPharma Credit (LON:BPCP) reported a higher share price and continued portfolio diversification in its half-year investor presentation, while manager Pharmakon said it is managing cash to support new lending opportunities and potential future repayments. Pedro Gonzalez de Cosio, chief executive o

Idorsia (SWX:IDIA) continues to attract attention after recent share price moves, with the stock down 4.5% on the latest trading day and showing weaker performance over the past month and the past three months. Short term momentum for Idorsia looks weak, with the share price falling 11% over the past week and 22% over the past month. However, the year to date share price return of 7% and 1-year total shareholder return of 17% suggest the longer term picture has been more supportive. Spot...

Idorsia has given investors a wild ride over the past few years, and the big question now is whether the current share price can be squared with the revenue the business is generating. With the stock having gone through both sharp gains and deep declines, the issue is how much of its sales power is already baked into today's valuation. Over the last 5 years the share price has fallen 79.8%, which puts the spotlight firmly on whether the revenue base can support where the stock now...

Ad hoc announcement pursuant to Art. 53 LR The DEA states that dual orexin receptor antagonists “do not produce physical or psychological dependence”Lower schedule expected to enhance patient access in the US Allschwil, Switzerland – August 11, 2026Idorsia Ltd (SIX: IDIA) announces that the US Drug Enforcement Administration (DEA) will publish a proposed rule to reclassify dual orexin receptor antagonists (DORAs) from Schedule IV to Schedule V under the Controlled Substances Act (CSA). The propo

Idorsia Ltd (IDRSF) reports strong commercial momentum and strategic financing moves despite ongoing operational losses.

Ad hoc announcement pursuant to Art. 53 LR QUVIVIQ™ (daridorexant) sales reached CHF 91 million in H1 2026, up 62% year-on-year. Full-year 2026 guidance reaffirmed. Company focused on four key drivers of future growth.Allschwil, Switzerland – July 30, 2026Idorsia Ltd (SIX: IDIA), a commercial-stage biopharmaceutical company with a portfolio of first- or best-in-class assets, today announced its financial results for the first half of 2026. Jean-Paul Clozel, Chairman and interim CEO of Idorsia, c

Exclusive agreement with Jamjoom Pharma covers commercialization and distribution of QUVIVIQ™ (daridorexant) in Saudi Arabia and the Levant region Allschwil, Switzerland – July 27, 2026Idorsia Ltd (SIX: IDIA) has entered into an exclusive agreement with Jamjoom Pharmaceuticals Factory Co. (“Jamjoom Pharma”) for the distribution and commercialization of QUVIVIQ™ (daridorexant), Idorsia’s treatment for adults with insomnia, in Saudi Arabia and the Levant region. Benjamin Limal, President of Europe

Idorsia will publish its Half Year 2026 Financial Reporting on Thursday July 30, at 07:00 CEST. An investor webcast and conference call will be held to discuss the results on the same day. Date: Thursday, July 30, 2026 Time: 14:00 CEST / 13:00 BST / 08:00 EDT The call will start with presentations by senior management, followed by a Q&A session. Live Webcast (audio + slides):The live webcast can be accessed from the Idorsia website www.idorsia.com. Dial-in procedure for analysts (audio only): An

Ad hoc announcement pursuant to Art. 53 LR Idorsia appoints Roland Wandeler as CEO – effective October 1, 2026 – an experienced biopharmaceutical executive combining scientific expertise with business acumen to translate innovation into performance and lead Idorsia’s next phase of growthAllschwil, Switzerland – July 1, 2026Idorsia Ltd (SIX: IDIA) today announced the appointment of Roland Wandeler, PhD, as Chief Executive Officer (CEO), effective October 1, 2026. The appointment comes at a pivota

ROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative medicines for areas of significant unmet need, today announced the appointment of Srishti Gupta, MD MPP as Chief Executive Officer and a member of the Company's Board of Directors, effective July 1, 2026. Xi-Yong (Sean) Fu, PhD MBA will step down as Chief Executive Officer to pursue other opportunities. Dr. Fu will

Allschwil, Switzerland – June 26, 2026Idorsia Ltd (SIX: IDIA), a commercial-stage biopharmaceutical company with a portfolio of first- or best-in-class assets, today confirmed the successful closing of its previously announced senior secured term loan agreement of up to CHF 250 million with investment funds managed by Pharmakon Advisors, LP. At closing, Idorsia received the first tranche of CHF 150 million and partially used it to fully repay the CHF 105 million drawn under the previously existi

Recently published Insomnia Market Insights report includes a comprehensive understanding of current treatment practices, insomnia emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

If you are wondering whether Idorsia at CHF4.39 is still interesting after a strong run, the next sections will focus on what the current price might mean for value oriented investors. The stock has posted returns of 6.2% over the last 7 days, 19.2% over the last 30 days and 8.1% year to date, while the 1 year return stands at 166.4% against longer term declines of 45.5% over 3 years and 82.9% over 5 years. This mix of sharp recent gains and longer term weakness suggests that fresh...

High-dose cohort confirms the favorable safety profile and the dose-dependent immune response against Clostridioides difficile bacteria and spores Allschwil, Switzerland – June 1, 2026Idorsia Ltd (SIX: IDIA) today announced additional positive clinical results for IDOR-1134-2831, its vaccine targeting Clostridioides difficile (C. difficile) in a Phase 1 clinical pharmacology trial. The glycan target of this vaccine is present on both bacteria and spores – the transmissible form of the pathogen r

The findings demonstrate that aprocitentan may help reduce the risk of kidney disease progression, cardiovascular events, and mortality in patients with resistant hypertension. Allschwil, Switzerland – June 01, 2026Idorsia Ltd (SIX: IDIA) announces new analyses from the Phase 3 PRECISION study demonstrating that aprocitentan, Idorsia’s dual endothelin receptor antagonist, significantly reduces albuminuria and improves albuminuria risk categories in patients with resistant hypertension. The data

Allschwil, Switzerland – May 6, 2026At today’s Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted convincingly in favor of all proposals by the Board of Directors. The meeting was attended by 213 shareholders, representing a total of 107’812’120 shares, or 43% of the total outstanding shares. Jean-Paul Clozel, MD, Chairman of the Board of Directors and interim CEO of Idorsia, commented:“On behalf of the Board, I would like to thank our sharehol

Ad hoc announcement pursuant to Art. 53 LR Preparation is underway to publish the strong pediatric daridorexant data and engage with regulatory authorities on next stepsCo-promotion of QUVIVIQ is being expanded across additional European markets to further accelerate growthPartnering discussions for TRYVIO™/JERAYGO™ are ongoing with several parties Allschwil, Switzerland – April 28, 2026Idorsia Ltd (SIX: IDIA), a commercial-stage biopharmaceutical company with a portfolio of first- or best-in-cl

Idorsia’s analyst story has shifted again, with a new CHF 5 price target sitting alongside an unchanged fair value estimate of CHF 4.5. This reset reflects a mix of confidence in the company’s assets and concern around higher operating expenses and execution risks, as highlighted in recent analyst commentary. As you read on, you will see how these changing targets shape the evolving narrative and what to watch if you are tracking the stock. Stay updated as the Fair Value for Idorsia shifts by...

Allschwil, Switzerland – April 10, 2026Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting to approve the Annual Report of the year ending December 31, 2025, will be held on Wednesday, May 6, 2026, at 14.00 CEST at the Congress Center, Messe Basel, Switzerland. Notes to ShareholdersThe invitation was published in the Swiss Official Gazette of Commerce (Schweizerisches Handelsamtsblatt) t